Characterization of neuropathology in the HIV-1 transgenic rat at different ages

Journal of Neuroimmunology

Volumn 292, Issue , 2016, Pages 116-125

  Reid, William C ^a   Ibrahim, Wael G ^a   Kim, Saejeong J ^a   Denaro, Frank ^b   Casas, Rafael ^a   Lee, Dianne E ^a   Maric, Dragan ^c   Hammoud, Dima A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MORGAN STATE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Astrocytic loss; HIV 1 transgenic rat; Neuro HIV; Neuropathology; Neurotoxicity; Viral proteins

Indexed keywords

GLYCOPROTEIN GP 120; ACTIN BINDING PROTEIN; AIF1 PROTEIN, RAT; CALCIUM BINDING PROTEIN; CD11B ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; TYROSINE 3 MONOOXYGENASE;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL DAMAGE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE; MALE; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RAT; RAT MODEL; TRANSGENIC RAT; AGING; ANIMAL; BRAIN; CASE CONTROL STUDY; CEREBROSPINAL FLUID; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; HIV ASSOCIATED NEPHROPATHY; HUMAN; METABOLISM; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

AGING; AIDS-ASSOCIATED NEPHROPATHY; ANIMALS; ANTIGENS, CD11B; BRAIN; CALCIUM-BINDING PROTEINS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, VIRAL; GLIAL FIBRILLARY ACIDIC PROTEIN; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MALE; MICROFILAMENT PROTEINS; RATS; RATS, TRANSGENIC; TYROSINE 3-MONOOXYGENASE;

EID: 84960849299     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2016.01.022     Document Type: Article

References (77)

1. Abbondanzo S.J., Chang S.L. HIV-1 transgenic rats display alterations in immunophenotype and cellular responses associated with aging. PLoS One 2014, 9.
2. Agrawal L., Louboutin J.P., Reyes B.A., Van Bockstaele E.J., Strayer D.S. HIV-1 Tat neurotoxicity: a model of acute and chronic exposure, and neuroprotection by gene delivery of antioxidant enzymes. Neurobiol. Dis. 2012, 45:657-670.
3. Akkina R. New generation humanized mice for virus research: comparative aspects and future prospects. Virology 2013, 435:14-28.
4. Basselin M., Ramadan E., Igarashi M., Chang L., Chen M., Kraft A.D., et al. Imaging upregulated brain arachidonic acid metabolism in HIV-1 transgenic rats. J. Cereb. Blood Flow Metab. 2011, 31:486-493.
5. Berges B.K., Rowan M.R. The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology 2011, 8:65.
6. Bezzi P., Domercq M., Brambilla L., Galli R., Schols D., De Clercq E., et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat. Neurosci. 2001, 4:702-710.
7. Bieniasz P.D., Cullen B.R. Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. J. Virol. 2000, 74:9868-9877.
8. Borjabad A., Brooks A.I., Volsky D.J. Gene expression profiles Of HIV-1-infected glia and brain: toward better understanding of the role of astrocytes in HIV-1-associated neurocognitive disorders. J. NeuroImmune Pharmacol. 2010, 5:44-62.
9. Boska M.D., Dash P.K., Knibbe J., Epstein A.A., Akhter S.P., Fields N., et al. Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice. Mol. Neurodegener. 2014, 9:58.
10. Chang L., Wang G.J., Volkow N.D., Ernst T., Telang F., Logan J., et al. Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. NeuroImage 2008, 42:869-878.
11. Dash P.K., Gendelman H.E., Roy U., Balkundi S., Alnouti Y., Mosley R.L., et al. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS (London, England) 2012, 26:2135-2144.
12. Dash P.K., Gorantla S., Gendelman H.E., Knibbe J., Casale G.P., Makarov E., et al. Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J. Neurosci. 2011, 31:3148-3157.
13. Desplats P., Dumaop W., Smith D., Adame A., Everall I., Letendre S., et al. Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology 2013, 80:1415-1423.
14. El-Hage N., Podhaizer E.M., Sturgill J., Hauser K.F. Toll-like receptor expression and activation in astroglia: differential regulation by HIV-1 Tat, gp120, and morphine. Immunol. Investig. 2011, 40:498-522.
15. Eng L.F., Ghirnikar R.S., Lee Y.L. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem. Res. 2000, 25:1439-1451.
16. Epstein A.A., Narayanasamy P., Dash P.K., High R., Bathena S.P., Gorantla S., et al. Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infection. J. NeuroImmune Pharmacol. 2013, 8:1224-1238.
17. Everall I., Vaida F., Khanlou N., Lazzaretto D., Achim C., Letendre S., et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J. Neurovirol. 2009, 15:360-370.
18. Fitting S., Booze R.M., Mactutus C.F. HIV-1 proteins, tat and GP120, target the developing dopamine system. Curr. HIV Res. 2015, 13:21-42.
19. Frade J.M., Ovejero-Benito M.C. Neuronal cell cycle: the neuron itself and its circumstances. Cell Cycle (Georgetown, Tex) 2015, 14:712-720.
20. Gelman B.B., Lisinicchia J.G., Morgello S., Masliah E., Commins D., Achim C.L., et al. Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J. Acquir. Immune Defic. Syndr. 2013, 62:487-495.
21. Gendelman H.E., Lipton S.A., Tardieu M., Bukrinsky M.I., Nottet H.S. The neuropathogenesis of HIV-1 infection. J. Leukoc. Biol. 1994, 56:389-398.
22. Gorantla S., Makarov E., Finke-Dwyer J., Castanedo A., Holguin A., Gebhart C.L., et al. Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis. Am. J. Pathol. 2010, 177:2938-2949.
23. Gray F., Scaravilli F., Everall I., Chretien F., An S., Boche D., et al. Neuropathology of early HIV-1 infection. Brain Pathol. (Zurich, Switzerland) 1996, 6:1-15.
24. Guo M, Bryant J, Sultana S, Jones O, Royal W, 3RD. Effects of vitamin a deficiency and opioids on parvalbumin + interneurons in the hippocampus of the HIV-1 transgenic rat. Curr. HIV Res. 2012;10:463-8.
25. Hu S., Sheng W.S., Lokensgard J.R., Peterson P.K., Rock R.B. Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage. J. Neurovirol. 2009, 15:401-410.
26. Imai Y., Kohsaka S. Intracellular signaling in M-CSF-induced microglia activation: role of Iba1. Glia 2002, 40:164-174.
27. Jiang B., Deng Y., Suen C., Taha M., Chaudhary K.R., Courtman D.W., et al. Marked strain-specific differences in the SU5416 rat model of severe pulmonary arterial hypertension. Am. J. Respir. Cell Mol. Biol. 2015.
28. Joshi P.C., Raynor R., Fan X., Guidot D.M. HIV-1-transgene expression in rats decreases alveolar macrophage zinc levels and phagocytosis. Am. J. Respir. Cell Mol. Biol. 2008, 39:218-226.
29. Kovalevich J., Langford D. Neuronal toxicity in HIV CNS disease. Futur. Virol. 2012, 7:687-698.
30. Kumar A.M., Fernandez J.B., Singer E.J., Commins D., Waldrop-Valverde D., Ownby R.L., et al. Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J. Neurovirol. 2009, 15:257-274.
31. Kumar A.M., Ownby R.L., Waldrop-Valverde D., Fernandez B., Kumar M. Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. J. Neurovirol. 2011.
32. Lashomb A.L., Vigorito M., Chang S.L. Further characterization of the spatial learning deficit in the human immunodeficiency virus-1 transgenic rat. J. Neurovirol. 2009, 15:14-24.
33. Lawrence D.M., Major E.O. HIV-1 and the brain: connections between HIV-1-associated dementia, neuropathology and neuroimmunology. Microbes Infect.Inst. Pasteur 2002, 4:301-308.
34. Lee K.M., Chiu K.B., Renner N.A., Sansing H.A., Didier P.J., Maclean A.G. Form follows function: astrocyte morphology and immune dysfunction in SIV neuroAIDS. J. Neurovirol. 2014, 20:474-484.
35. Lee D.E., Reid W.C., Ibrahim W.G., Peterson K.L., Lentz M.R., Maric D., et al. Imaging dopaminergic dysfunction as a surrogate marker of neuropathology in a small-animal model of HIV. Mol. Imaging 2014, 13:1-10.
36. Lee M.H., Amin N.D., Venkatesan A., Wang T., Tyagi R., Pant H.C., et al. Impaired neurogenesis and neurite outgrowth in an HIV-GP120 transgenic model is reversed by exercise via BDNF production and CDK5 regulation. J. Neurovirol. 2013, 19:418-431.
37. Lefesvre P., Attema J., Van Bekkum D. Pharmacogenetic heterogeneity of transgene expression in muscle and tumours. BMC Pharmacol. 2003, 3:11.
38. Lentz M.R., Peterson K.L., Ibrahim W.G., Lee D.E., Sarlls J., Lizak M.J., et al. Diffusion tensor and volumetric magnetic resonance measures as biomarkers of brain damage in a small animal model of HIV. PLoS One 2014, 9.
39. Liu X., Chang L., Vigorito M., Kass M., Li H., Chang S.L. Methamphetamine-induced behavioral sensitization is enhanced in the HIV-1 transgenic rat. J. NeuroImmune Pharmacol. 2009, 4:309-316.
40. Mcarthur J.C., Haughey N., Gartner S., Conant K., Pardo C., Nath A., et al. Human immunodeficiency virus-associated dementia: an evolving disease. J. Neurovirol. 2003, 9:205-221.
41. Mcarthur J.C., Steiner J., Sacktor N., Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann. Neurol. 2010, 67:699-714.
42. Merrill J.E., Chen I.S. HIV-1, macrophages, glial cells, and cytokines in aids nervous system disease. FASEB J. 1991, 5:2391-2397.
43. Mestre H., Ramirez M., Garcia E., Martinon S., Cruz Y., Campos M.G., et al. Lewis, Fischer 344, and Sprague-Dawley rats display differences in lipid peroxidation, motor recovery, and rubrospinal tract preservation after spinal cord injury. Front. Neurol. 2015, 6:108.
44. Midde N.M., Gomez A.M., Harrod S.B., Zhu J. Genetically expressed HIV-1 viral proteins attenuate nicotine-induced behavioral sensitization and alter mesocorticolimbic ERK and CREB signaling in rats. Pharmacol. Biochem. Behav. 2011, 98:587-597.
45. Mocchetti I., Bachis A., Avdoshina V. Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport. Neurotox. Res 2011.
46. Moran L.M., Aksenov M.Y., Booze R.M., Webb K.M., Mactutus C.F. Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge. Curr. HIV Res. 2012, 10:415-424.
47. Moran L.M., Booze R.M., Mactutus C.F. Time and time again: temporal processing demands implicate perceptual and gating deficits in the HIV-1 transgenic rat. J. NeuroImmune Pharmacol. 2013, 8:988-997.
48. Moran L.M., Booze R.M., Mactutus C.F. Modeling deficits in attention, inhibition, and flexibility in hand. J. NeuroImmune Pharmacol. 2014, 9:508-521.
49. Moran L.M., Booze R.M., Webb K.M., Mactutus C.F. Neurobehavioral alterations in HIV-1 transgenic rats: evidence for dopaminergic dysfunction. Exp. Neurol. 2013, 239:139-147.
50. Nemeth C.L., Glasper E.R., Harrell C.S., Malviya S.A., Otis J.S., Neigh G.N. Meloxicam blocks neuroinflammation, but not depressive-like behaviors, in HIV-1 transgenic female rats. PLoS One 2014, 9.
51. Noorbakhsh F., Ramachandran R., Barsby N., Ellestad K.K., Leblanc A., Dickie P., et al. MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival. FASEB J. 2010, 24:1799-1812.
52. Ohsawa K., Imai Y., Sasaki Y., Kohsaka S. Microglia/macrophage-specific protein Iba1 binds to fimbrin and enhances its actin-bundling activity. J. Neurochem. 2004, 88:844-856.
53. Peng J., Vigorito M., Liu X., Zhou D., Wu X., Chang S.L. The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART. J. Neuroimmunol. 2010, 218:94-101.
54. Plachez C., Martin A., Guiramand J., Recasens M. Astrocytes repress the neuronal expression of GLAST and GLT glutamate transporters in cultured hippocampal neurons from embryonic rats. Neurochem. Int. 2004, 45:1113-1123.
55. Radja F., Kay D.G., Albrecht S., Jolicoeur P. Oligodendrocyte-specific expression of human immunodeficiency virus type 1 Nef in transgenic mice leads to vacuolar myelopathy and alters oligodendrocyte phenotype in vitro. J. Virol. 2003, 77:11745-11753.
56. Reid W., Sadowska M., Denaro F., Rao S., Foulke J., Hayes N., et al. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:9271-9276.
57. Repunte-Canonigo V., Lefebvre C., George O., Kawamura T., Morales M., Koob G.F., et al. Gene expression changes consistent with neuroAIDS and impaired working memory in HIV-1 transgenic rats. Mol. Neurodegener. 2014, 9:26.
58. Robillard K.R., Hoque M.T., Bendayan R. Expression of ATP-binding cassette membrane transporters in a HIV-1 transgenic rat model. Biochem. Biophys. Res. Commun. 2014, 444:531-536.
59. Royal W., Zhang L., Guo M., Jones O., Davis H., Bryant J.L. Immune activation, viral gene product expression and neurotoxicity in the HIV-1 transgenic rat. J. Neuroimmunol. 2012, 247:16-24.
60. Shin A.H., Thayer S.A. Human immunodeficiency virus-1 protein Tat induces excitotoxic loss of presynaptic terminals in hippocampal cultures. Mol. Cell. Neurosci. 2013, 54:22-29.
61. Silverstein P.S., Shah A., Weemhoff J., Kumar S., Singh D.P., Kumar A. HIV-1 gp120 and drugs of abuse: interactions in the central nervous system. Curr. HIV Res. 2012, 10:369-383.
62. Siviy S.M., Mcdowell L.S., Eck S.R., Turano A., Akopian G., Walsh J.P. Effects of amphetamine on striatal dopamine release, open-field activity, and play in Fischer 344 and Sprague-Dawley rats. Behav. Pharmacol. 2015, 26:720-732.
63. Stozicka Z., Zilka N., Novak P., Kovacech B., Bugos O., Novak M. Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease. J. Neuroinflammation 2010, 7:64.
64. Sultana S., Li H., Puche A., Jones O., Bryant J.L., Royal W. Quantitation of parvalbumin+ neurons and human immunodeficiency virus type 1 (HIV-1) regulatory gene expression in the HIV-1 transgenic rat: effects of vitamin a deficiency and morphine. J. Neurovirol. 2010, 16:33-40.
65. Ton H., Xiong H. Astrocyte dysfunctions and HIV-1 neurotoxicity. J. Aids Clin. Res. 2013, 4:255.
66. Torres L., Noel R.J. Astrocytic expression of HIV-1 viral protein R in the hippocampus causes chromatolysis, synaptic loss and memory impairment. J. Neuroinflammation 2014, 11:53.
67. Vigorito M., Connaghan K.P., Chang S.L. The HIV-1 transgenic rat model of neuroHIV. Brain Behav. Immun. 2015.
68. Vigorito M., Lashomb A.L., Chang S.L. Spatial learning and memory in HIV-1 transgenic rats. J. NeuroImmune Pharmacol. 2007, 2:319-328.
69. Von Bohlen Und Halbach O. Immunohistological markers for proliferative events, gliogenesis, and neurogenesis within the adult hippocampus. Cell Tissue Res. 2011, 345:1-19.
70. Wang Z., Pekarskaya O., Bencheikh M., Chao W., Gelbard H.A., Ghorpade A., et al. Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or GP120. Virology 2003, 312:60-73.
71. Wang Z., Trillo-Pazos G., Kim S.Y., Canki M., Morgello S., Sharer L.R., et al. Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis. J. Neurovirol. 2004, 10(Suppl. 1):25-32.
72. Wayman W.N., Chen L., Persons A.L., Napier T.C. Cortical consequences of HIV-1 Tat exposure in rats are enhanced by chronic cocaine. Curr. HIV Res. 2015, 13:80-87.
73. Webb K.M., Aksenov M.Y., Mactutus C.F., Booze R.M. Evidence for developmental dopaminergic alterations in the human immunodeficiency virus-1 transgenic rat. J. Neurovirol. 2010, 16:168-173.
74. Wolf H.K., Buslei R., Schmidt-Kastner R., Schmidt-Kastner P.K., Pietsch T., Wiestler O.D., et al. NeuN: a useful neuronal marker for diagnostic histopathology. J. Histochem. Cytochem. 1996, 44:1167-1171.
75. Yadav A., Collman R.G. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J. NeuroImmune Pharmacol. 2009, 4:430-447.
76. Zeiss C.J. Neuroanatomical phenotyping in the mouse: the dopaminergic system. Vet. Pathol. 2005, 42:753-773.
77. Zhang L., Su L. HIV-1 immunopathogenesis in humanized mouse models. Cell. Mol. Immunol. 2012, 9:237-244.